Tipranavir

Zelalem Temesgen, Francesca Cainelli, Sandro Vento

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Tipranavir is a newly approved protease inhibitor that belongs to the class of 4-hydroxy-5,6-dyhydro-2-pyrones. It exhibits potent in vitro activity against both human immunodeficiency virus (HIV)-1 and HIV-2, including clinical isolates with multiple protease inhibitor-resistant mutations. Tipranavir requires coadministration with ritonavir to achieve clinically meaningful serum concentration. In randomized, phase III, open-label trials, it was found to be superior to the currently available boosted protease inhibitors in highly treatment-experienced patients with multiple protease inhibitor mutations. Thus, it provides a welcome new option for salvage antiretroviral therapy. The most common adverse effects associated with tipranavir are diarrhea, nausea and vomiting. Common laboratory abnormalities include elevations of total cholesterol, triglycerides and liver enzymes.

Original languageEnglish
Pages (from-to)711-720
Number of pages10
JournalDrugs of Today
Volume41
Issue number11
DOIs
Publication statusPublished - Nov 2005
Externally publishedYes

Fingerprint

Protease Inhibitors
Ritonavir
Salvage Therapy
Mutation
HIV-2
Nausea
Vomiting
HIV-1
Diarrhea
Triglycerides
Cholesterol
tipranavir
Liver
Enzymes
Serum
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Tipranavir. / Temesgen, Zelalem; Cainelli, Francesca; Vento, Sandro.

In: Drugs of Today, Vol. 41, No. 11, 11.2005, p. 711-720.

Research output: Contribution to journalReview article

Temesgen, Zelalem ; Cainelli, Francesca ; Vento, Sandro. / Tipranavir. In: Drugs of Today. 2005 ; Vol. 41, No. 11. pp. 711-720.
@article{e39324085d1d4c708d0f3b81743f318e,
title = "Tipranavir",
abstract = "Tipranavir is a newly approved protease inhibitor that belongs to the class of 4-hydroxy-5,6-dyhydro-2-pyrones. It exhibits potent in vitro activity against both human immunodeficiency virus (HIV)-1 and HIV-2, including clinical isolates with multiple protease inhibitor-resistant mutations. Tipranavir requires coadministration with ritonavir to achieve clinically meaningful serum concentration. In randomized, phase III, open-label trials, it was found to be superior to the currently available boosted protease inhibitors in highly treatment-experienced patients with multiple protease inhibitor mutations. Thus, it provides a welcome new option for salvage antiretroviral therapy. The most common adverse effects associated with tipranavir are diarrhea, nausea and vomiting. Common laboratory abnormalities include elevations of total cholesterol, triglycerides and liver enzymes.",
author = "Zelalem Temesgen and Francesca Cainelli and Sandro Vento",
year = "2005",
month = "11",
doi = "10.1358/dot.2005.41.11.937960",
language = "English",
volume = "41",
pages = "711--720",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - Tipranavir

AU - Temesgen, Zelalem

AU - Cainelli, Francesca

AU - Vento, Sandro

PY - 2005/11

Y1 - 2005/11

N2 - Tipranavir is a newly approved protease inhibitor that belongs to the class of 4-hydroxy-5,6-dyhydro-2-pyrones. It exhibits potent in vitro activity against both human immunodeficiency virus (HIV)-1 and HIV-2, including clinical isolates with multiple protease inhibitor-resistant mutations. Tipranavir requires coadministration with ritonavir to achieve clinically meaningful serum concentration. In randomized, phase III, open-label trials, it was found to be superior to the currently available boosted protease inhibitors in highly treatment-experienced patients with multiple protease inhibitor mutations. Thus, it provides a welcome new option for salvage antiretroviral therapy. The most common adverse effects associated with tipranavir are diarrhea, nausea and vomiting. Common laboratory abnormalities include elevations of total cholesterol, triglycerides and liver enzymes.

AB - Tipranavir is a newly approved protease inhibitor that belongs to the class of 4-hydroxy-5,6-dyhydro-2-pyrones. It exhibits potent in vitro activity against both human immunodeficiency virus (HIV)-1 and HIV-2, including clinical isolates with multiple protease inhibitor-resistant mutations. Tipranavir requires coadministration with ritonavir to achieve clinically meaningful serum concentration. In randomized, phase III, open-label trials, it was found to be superior to the currently available boosted protease inhibitors in highly treatment-experienced patients with multiple protease inhibitor mutations. Thus, it provides a welcome new option for salvage antiretroviral therapy. The most common adverse effects associated with tipranavir are diarrhea, nausea and vomiting. Common laboratory abnormalities include elevations of total cholesterol, triglycerides and liver enzymes.

UR - http://www.scopus.com/inward/record.url?scp=30444449824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444449824&partnerID=8YFLogxK

U2 - 10.1358/dot.2005.41.11.937960

DO - 10.1358/dot.2005.41.11.937960

M3 - Review article

VL - 41

SP - 711

EP - 720

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 11

ER -